New York and Dusseldorf, Germany and Tokyo –(Business Wire) — Asahi Kasei Pharma, a subsidiary of diversified Japanese multinational corporation Asahi Kasei, has publicly called for new proposals for drug development research, as part of its open innovation efforts to promote drug discovery through enhanced collaboration with universities, research institutes and businesses around the world. The application period begins on January 5, 2023 at 5:00 am GMT and ends on February 28, 2023 at 8:00 am GMT.
Asahi Kasei Pharma established the Open Innovation Unit in October 2016 with the mission to further strengthen and enhance global licensing and alliance building activities and has since funded an average of about 5 proposals per year, with a total of over 20 funding proposals status – state-of-the-art drug development and a rich collection of creative new ideas. The Open Innovation team is seeking up to $200,000 per year in innovation proposal funding for each project in this upcoming 2023 funding round. Asahi Kasei Pharma will then pursue joint research opportunities with drug discovery researchers and its parent company in the hope of creating new innovative medicines for diseases with currently unmet needs, or pioneering new platform technologies for drug discovery.
Asahi Kasei Pharma has a successful track record in the development of new drugs in the fields of autoimmune, renal, neurological and skeletal diseases, so the organization can make the greatest contribution from related research fields and disciplines.
“Asahi Kasei Pharma believes that no one should give up what they want to do because of illness,” said Osamu Matsuzaki, CEO and Head of R&D and Business Development at Asahi Kasei Pharma.We believe great science comes from collaboration, and we’re excited to have the opportunity to work with researchers around the world on this mission. ”
Open Innovation is committed to establishing research collaborations related to innovative drug targets and drug candidate compounds, through to the preclinical stage and advanced drug discovery technologies. Advances in exploring new mechanisms of action for the treatment of refractory autoimmune disease are one of the most promising results of this research to date, with more to come. Asahi Kasei believes that these continued efforts to advance drug discovery and research technologies will further contribute to the lives and livelihoods of people around the world.
Request for Proposal Summary
Target applicants:
Researchers at universities, research institutes, and companies outside Japan
(Researchers in Japan should refer to the Japanese website)
Research areas and topics:
-
Autoimmune Diseases – New Drug Candidates and New Drug Development Technologies
-
Kidney Disease – New Drug Candidates and New Drug Development Technologies
-
Pain and Neurodegenerative Diseases – New Drug Candidates and New Drug Development Technologies
-
Bone disease – new drug candidates
-
Drug Discovery Platform Technologies – Drug Formulations, Analytical Methods and Organic Synthesis
funds:
Up to $200,000 per year per selected proposal
Research period:
1-3 years (Milestones are set every year, and research content is reviewed as needed based on research results)
Submissions will be assessed for their potential as a concept for collaborative research and research promotion. For more information, visit Asahi Kasei Pharma’s Open Innovation website.
About Asahi Kasei Pharmaceuticals
According to the mission,We sincerely care for each person’s life with rich ideas and solid science, and solve their unmet medical needs,” said Asahi Kasei Pharma, which operates the pharmaceutical and diagnostics business within the healthcare division of the Asahi Kasei Group. Numerous innovative medicines have been developed in the fields of monitoring, musculoskeletal and other rare diseases, contributing to society by providing highly innovative medicines to patients with previously unmet diseases.
For more information, visit https://www.asahikasei-pharma.co.jp/en/.
About Asahi Kasei
The Asahi Kasei Group contributes to the lives and lives of people around the world. Since the establishment of the ammonia and cellulose fiber business in 1922, Asahi Kasei has continued to grow by actively transforming its business portfolio to meet the changing needs of each era. With more than 46,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world’s challenges through its Materials, Home and Healthcare business units. Its healthcare business includes equipment and systems for acute intensive care, dialysis, therapeutic apheresis, blood transfusion and the manufacture of biotherapeutics as well as pharmaceuticals and diagnostics. For more information, please visit https://www.asahi-kasei.com/.
Asahi Kasei is also working on sustainable development plans and contributing to a carbon neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability/.